LVMUY-OTC 0 ACN-N -0.98 UNH-N -4.91 VALT-T 0.19 MART-T -0.15 VIDY-T 0.31 RPRX-Q 0.05
Daily Stock Opinions and Ratings
Stockchase Opinions

The Weekly Buzzing Stocks by Billy Kawasaki CRISPR Therapeutics AG CRSP-Q TOP PICK Apr 08, 2022

Biopharmaceutical company building gene editing based medicines for serious diseases. Riskier play, but gene editing would be a massive breakthrough and they have been the leaders in that space for a while. New to the trending stocks with 13 mentions in the past 24 hours.
The Weekly Buzzing Stocks by Billy KawasakiThe Weekly Buzzing Stocks by Billy Kawasaki
Unknown
$61.620

Stock price when the opinion was issued

biotechnology
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.
Get Signals Create your Watchlist

You might be interested:

COMMENT

CRISPR Therapeutics AG(CRSP-Q)

Apr 25, 2019
They produce a gene-editing tool that splices DNA that has the potential of curing diseases such as Huntington's Chorea and cancer. It's new technology, but he can't think of another company doing this. This segment is very rich and a trading opportunity at best.
Darren SissonsDarren Sissons
Unknown
Unlock Rating
$39.560

Stock price when the opinion was issued

biotechnology
COMMENT

CRISPR Therapeutics AG(CRSP-Q)

Jun 12, 2019
A small company that develops transformative gene medications. They are a small fish in a big sea. A recent transaction with a pharma company allows them to scale out their product, but it is still early. (Analysts’ price target is $58.05)
Kim BoltonKim Bolton
Unknown
Unlock Rating
$43.530

Stock price when the opinion was issued

biotechnology
RISKY

CRISPR Therapeutics AG(CRSP-Q)

Mar 22, 2021
A great spec. It's a genetic engineering company so it's bought on spec, not earnings.
Jim Cramer - Mad MoneyJim Cramer - Mad Money
Unknown
Unlock Rating
$133.000

Stock price when the opinion was issued

biotechnology
DON'T BUY

CRISPR Therapeutics AG(CRSP-Q)

Jun 07, 2022
Their gene-editing biotechnology has lots of promise, but it's too early to tell, speculative. Buying this is a lottery ticket.
Jamie Murray Jamie Murray
No
Unlock Rating
$67.375

Stock price when the opinion was issued

biotechnology
HOLD

CRISPR Therapeutics AG(CRSP-Q)

Dec 29, 2023

Recent improvements in R&D have been major gain in the business. Is hard to predict future of business given nature of health discoveries. Would recommend holding it. 

Brendan CaldwellBrendan Caldwell
Unknown
Unlock Rating
$62.610

Stock price when the opinion was issued

biotechnology
BUY

CRISPR Therapeutics AG(CRSP-Q)

Aug 07, 2024

They have some explosive technology. He believes in it.

Jim Cramer - Mad MoneyJim Cramer - Mad Money
Unknown
Unlock Rating
$47.430

Stock price when the opinion was issued

biotechnology
COMMENT

CRISPR Therapeutics AG(CRSP-Q)

Oct 11, 2024

Is trading at a fraction of a few years ago. If you know about gene technology, maybe buy this, but doesn't know a lot about this science or business.

Brendan CaldwellBrendan Caldwell
No
Unlock Rating
$46.850

Stock price when the opinion was issued

biotechnology
PARTIAL BUY

CRISPR Therapeutics AG(CRSP-Q)

Jan 06, 2025

He sees this company mentioned in many science papers, but the stock has been a tough own. Overall, he likes it. Buy some now and more if it goes lower. How can this company keep losing money?

Jim Cramer - Mad MoneyJim Cramer - Mad Money
Unknown
Unlock Rating
$42.430

Stock price when the opinion was issued

biotechnology

Build our watch list

Sign in to track investments
you care about

Latest Buy Signals

AAXN-Q -2.24$684.59
RKLB-Q -2.59$20.51
ENB-T 0.51$64.3
CLF-N -0.15$7
PLTR-Q -1.85$117.3

Today's Top Picks

LVMUY-… 0$109.799
ACN-N -0.98$307.9
UNH-N -4.91$380.64
VALT-T 0.19$40.79
MART-T -0.15$22.75

Popular Articles

Latest Sell Signals

GOOG-Q -1.37$154.38
VRTX-Q -4.61$424.99
PLTR-Q -1.85$117.3
ZTS-N -2.42$159.27
ADBE-Q -0.71$383.28

Most Recent Experts

Stockchase Insights

Stockchase Insights

5i Research

Michael Hakes - CFA, MBA

Michael Hakes - CFA, MBA

Murray Wealth Group

Stephen Weiss, Founder, Short Hills Capital Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Jim Lebenthal

Jim Lebenthal

Cerity Partners

Brenda Vingiello, CIO, Sand Hill Global Advisors

Brenda Vingiello, CIO, Sand Hill Global Advisors

Sand Hill Global Advisors

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: hello@stockchase.com.

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© Stockchase Inc. by Wealthica